Loss-of-function of ten-eleven translocation-2 (TET2) is a common event in myeloid malignancies, and plays pleiotropic roles, including augmenting stem cell self-renewal and skewing hematopoietic cells to the myeloid lineage. TET2 mutation has also been reported in lymphoid malignancies; 5.7∼12% of diffuse large B-cell lymphomas and 18∼83% of angioimmunoblastic T-cell lymphomas had TET2 mutations. We investigated TET2 mutations in 22 adult T-cell leukemia/lymphoma (ATLL) patients and identified a missense mutation in 3 cases (14%). TET2 mutation occurred in a number of ATLL patients and was likely involved in their leukemogenesis.
INTRODUCTION
Adult T-cell leukemia/lymphoma (ATLL) is an aggressive T-cell neoplasm caused by human T-cell leukemia virus type 1 (HTLV-1). [1] [2] [3] Retroviral HTLV-1 is transmitted to neonatal CD4 + T-cells through breast-feeding by cell-to-cell transmission. Proviral DNA is generated from genomic viral RNA, followed by random integration into the host genome. After a latency period of 40-60 years, gene mutations accumulate in HTLV-1-infected CD4 + T-cells, and ATLL develops in about 3-5% of HTLV-1-infected individuals.
Somatic mutations in Ten-Eleven Translocation-2 (TET2) were first identified in myeloproliferative neoplasms (MPN) and myelodysplastic syndromes. 4, 5 TET2 plays a key role in the conversion of 5-methyl-cytosine to 5-hydroxymethyl cytosine (5-hmC), and TET2 mutations, including deletions, missense, nonsense, and frameshift mutations, were shown to result in loss-of-function of TET2 and a marked reduction in global levels of 5-hmC. 6 We and others reported that TET2-deficient hematopoietic stem cells showed increased selfrenewal ability and exhibited a competitive growth advantage over wild-type hematopoietic stem cells. [7] [8] [9] [10] In addition to myeloid malignancies, TET2 mutations have been detected in B-lineage and T-lineage lymphoid malignancies. [11] [12] [13] [14] [15] Of these, TET2 was most frequently mutated in angioimmunoblastic T-cell lymphomas and "Th follicular (TFH) -like" peripheral T-cell lymphomas, not otherwise specified. [12] [13] [14] Because ATLL is a type of peripheral Tcell lymphoma, we investigated 22 ATLL patients for TET2 mutation and identified 3 patients with missense mutations.
MATERIALS AND METHODS

Patients and tumor samples
A series of 22 ATLL patients with frozen tumor cell samples available were selected. The specimens were collected between 2005 and 2011, with 70% between 2008 and 2011. These samples were not included in the sample set used for the genome-wide analysis of ATLL we recently published. 16 Medical records were reviewed for clinical data. Diagnosis of ATLL was based on clinical features, cytologically-proven mature T-cell malignancy, the presence of anti-HTLV-1 antibodies, and monoclonal integration of HTLV-1 proviral DNA into tumor cells, as confirmed by Southern blotting. This study was approved by the Research Ethics Committee of University of Miyazaki.
TET2 genotyping
DNA was extracted from frozen cells using a standard protocol. The coding sequence of the TET2 gene (exons 3 through 10) was amplified by the polymerase chain reaction (PCR) method with the GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA). The sequences of the PCR primers used for TET2 were designed as described in a previous report, 17 and purchased from Hokkaido System Science Co., Ltd. Nucleotide sequences were determined by fluorescent dye chemistry sequencing with an ABI PRISM3000 DNA Analyzer (Applied Biosystems and analyzed with Sequencing Analysis software (Applied Biosystems). The presence of mutations or single nucleotide polymorphisms was determined by referencing the assembled sequence in the Ensembl genome database.
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Interpretation of mutations
To predict whether the identified TET2 mutations may have deleterious effects, we used two online software programs, Sorting Intolerant from Tolerant (SIFT; http: //sift. jcvi.org/webcite) 19 and Polymorphism Phenotyping v2 (Polyphen-2; http: //genetics. bwh. harvard. edu/pph2/ webcite). 20 SIFT uses sequence homology to predict amino acid substitutions that may affect protein function. SIFT scores range from 0 to 1, and scores < 0.05 suggest that the amino acid change is not tolerated. 19 PolyPhen-2 uses straightforward physical and comparative considerations to predict the possible impact of an amino acid substitution on the structure and function of a human protein. Polyphen-2 scores > 0. 85 are interpreted as probably damaging, and scores 0.15-0.85 as possibly damaging.
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RESULTS
Subject characteristics are listed in Table 1 . Of the 22 patients, 15 were men and 7 were women. The median age was 67. 5 years (range, 51-83). Based on the Shimoyama criteria, 21 7 cases were diagnosed as lymphoma-type ATLL, and 14 cases with more than one of the following observations were diagnosed as acute-type ATLL: lactate dehydrogenase greater than twice the normal upper limit, Ca 2+ > 11.0 mg/dL, and multiple organ ATLL involvement. One case was not classified due to the lack of lymphocyte-related data. ATLL cells were obtained from lymph nodes in 17 cases, from a skin tumor in 1 case, from sinusoid tumors in 2 cases, and from subcutaneous tumors in 2 cases. The surface markers of the ATLL cells were analyzed by flow cytometry in 13 The result of immunohistochemical staining of tumors samples are shown as +, ±, or −, corresponding to positive, weak positive, or negative, respectively. The Arabic number indicates the positive rate (%) of cell surface antigen by means of flow cytometric analysis. ATLL, adult T-cell leukemia/lymphoma; WBC, white blood cell; LDH, lactate dehydrogenase; sIL-2R, soluble interleukin-2 receptor; LNs, lymph nodes; n.d., not done and CD4 -CD8 -in 1 case. The remaining 3 cases were characterized as follows: in 1 case, both CD4 and CD8 were weakly positive by immunohistochemistry; in 1 case, CD4 was positive but the status of CD8 was undetermined; and in 1 case, the status of neither CD4 nor CD8 was examined. In 9 patients, the proportion of infiltrated ATLL cells in each sample was analyzed by pathological examination. Except for case number 6, ATLL cells constituted more than half of the cells in the sample.
We examined the entire coding sequences of the TET2 gene (exons 3-10) in 22 ATLL patients, and found a silent mutation in 1 patient (case 3) and missense mutations in 3 patients (cases 12, 14, and 20) . In addition, 6 types of single nucleotide polymorphisms, as determined from referencing the base sequence in the Ensembl genome database (http:// www.ensembl.org/Homo_sapiens/Transcript/Sequence_ cDNA?db=core;g=ENSG00000162434;r=1:65071494-65204775;t=ENST00000342505), were identified in 15 cases, including 3 patients with mutations (cases 3, 14, and 20).
The missense mutations observed in cases 12, 14, and 20 were c.2440 C > T, c.2604 T > G, and c.3722 C > A, respectively, which led to amino acid substitutions from p.814 arginine (R) to cysteine (C), p.868 phenylalanine (F) to leucine (L), and p.1241 alanine (A) to aspartic acid (D), respectively. SIFT and PolyPhen-2 were used to predict the possible effects of these missense mutations on TET2. The SIFT scores of R814C, F868L, and A1241D were 0, 0.01, and 0, respectively, suggesting that these 3 missense mutations were deleterious. Furthermore, the PolyPhen-2 scores of R814C, F868L, and A1241D were 0.006, 0.169, and 0.971, respectively, indicating that these mutations were benign, possibly damaging, and probably damaging, respectively.
As of the end-of October 2015, two patients remained alive, one with a TET2 missense mutation and the other without TET2 mutation. The overall survival of ATLL patients with or without TET2 mutation is shown in Fig. 1 .
DISCUSSION
We identified three TET2 missense mutations, R814C, F868L, and A1241D, in three different patients in our study population of 22 ATLL cases. Independent of this study, we recently performed a genome-wide analysis of ATLL cells and observed TET2 mutation in approximately 10% of ATLL patients. 16 In these two independent ATLL cohorts, TET2 mutation was observed with approximately the same frequency.
TET2 missense mutations have been reported to occur throughout the gene. 22 In particular, A1241D is located in a cysteine-rich domain that is the most frequently mutated region of TET2 in myeloid disorders 22 and diffuse large B-cell lymphomas. 15 The mutations identified in this study were ATLL, adult T-cell leukemia/lymphoma; TET2, ten-eleven translocation-2 evaluated using in silico analysis methods for predicting the mutational effects on protein function, and 2 of the mutations were determined to be damaging to protein function by both in silico methods. Because TET2 catalyzes the conversion of 5-methyl-cytosine to 5-hmC, deleterious mutations would affect the global methylation status of genes. In fact, TET2 mutations are associated with hypermethylation within CpG islands, and at CpG-rich promoters of genes involved in hema topoietic differentiation and cellular development in diffuse large B-cell lymphoma. Furthermore, 11% of the hypermeth ylated genes, which include several tumor suppressor genes, were reported to be down-regulated. In ATLL, epigenetic changes to cell cycle regulator genes such as p53, p15, p14, and p16 have been reported, 23, 24 which may be due to TET2 mutation and its functional impairment.
We recently reported that TET2 loss-of-function played a dual role in MPN, as both a disease initiator and disease accelerator.
25 TET2 mutation was reported to be involved in the ontogeny of lymphoid malignancies. Some patients with a TET2-mutated myeloid malignancy developed lymphoma, and the same TET2 mutation was observed both in the primary myeloid malignancies and the secondary lymphoma, indicating that the two diseases have common ancestry. Furthermore, in angioimmunoblastic T-cell lymphoma, the same TET2 mutation was identified within both lymphoma and lineage-CD34 -CD38 + progenitors from G-CSFmobilized peripheral blood, indicating that TET2 mutation occurred at the stem/progenitor cell level and was an early event in lymphoma ontogeny. In addition, TET2 loss-offunction demonstrated altered T-and B-cell lineage development in a mouse model. 8 On the other hand, we reported that in MPN, TET2 loss-of-function led to acceleration of malignancy; 25 in this instance, TET2 mutation was thought to be a late genetic event. We could not definitively conclude whether TET2 mutation was an early genetic event or a late genetic event in the ATLL patients in this study, because we did not evaluate the TET2 mutational status in the myeloid lineage cells or hematopoietic progenitor cells due to the unavailability of patients' bone marrow samples.
In conclusion, TET2 mutation was identified in several ATLL patients, and was likely to be involved in their leukemogenesis. In this study, the number of patients with TET2 mutation was too small to elucidate specific clinical features associated with TET2 mutation in ATLL. Overall survival appeared approximately equal, regardless of the presence or absence of TET2 mutation. The accumulation of mutational analyses in a large number of ATLL patients will clarify the impact of TET2 mutations on the ATLL clinical course.
